The Good News On Cancer: FDA Approves Immunotherapy Cancer Drugs, Is This The Answer To Cancer?

The US Food and Drug Administration have recently approved three types of drugs in the immunotherapy class with the hopes of treating cancer. Accordingly, Assoc Prof Narin Voravud from the Chulalongkorn University Department of Medicine said that the FDA has allegedly approved three drugs that are set to be used for treating several types of cancer. It was found that due to its great potential and efficacy, Immunotherapy has been noted to be a new form of treatment that is found to be using a patient's own immune system to help ward off cancer cells.

FDA Approves Immunotherapy Cancer Drugs

In one of his statements reported by Bangkok Post, Prof Narin has revealed that the drugs had been approved particularly for the treatment of skin cancer, cancer of the large intestine, lung cancer, cancer of the bladder and cancer in the lymph nodes. Experts believe that these drugs that have been approved by the FDA are administrated by injection by medical doctors. Additionally, Dr. Narin has also clarified that although immunotherapy treatments might be a bit costly, patients who were treated this way were reported to have fewer side effects than patients who receive standard chemotherapy.

More Good News On Cancer

Meanwhile, according to The Chicago Tribune, Northwestern Medicine is currently on the move to fight up a notch, which is also believed to be co-leading a national trial to test an immunotherapy drug combination on people with rare cancers. Chief of hematology and oncology at Northwestern University's Feinberg School of Medicine, Dr. Frank Giles has described immunotherapy as a revolution since he believes that nothing will be the same after what the said occurrence. It was found that Dr. Giles has been allegedly one of four principal investigators on the study called DART, which is also being spearheaded by the University of California at San Diego.


© 2021 iTech Post All rights reserved. Do not reproduce without permission.

More from iTechPost